NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Exegenesis Bio

Exegenesis Bio

Private
Horsham, PennsylvaniaHealthcare & Life Scienceshttps://exegenesisbio.com/

Last Round

Series B

Extension

Jun 23, 2021

Total Funding Raised

$70M

Company Overview

Exegenesis Bio is a biotechnology company that develops cell and gene therapies to treat multiple diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Infrastructure

Keywords

gene therapyAAV gene therapyAI drug discoveryspinal muscular atrophySMAAAV capsid discoveryclinical-stage biotechgenerative biologyone-time gene therapyvector engineeringneovascular age-related macular degenerationnAMDCNS gene therapyFabry diseaseprotein engineeringcGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exegenesis Bio Comparables

Compare Exegenesis Bio with similar companies based on industry and business-model similarity.

Exegenesis Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Capsida Biotherapeutics
86%
Shanghai Refreshgene Technology Co., Ltd.
84%
Frontera Therapeutics
83%

Exegenesis Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJun 23, 2021
Series B ExtensionFeb 1, 2021
Series BAug 3, 2020

Key People

Founding team and executive leadership

Zhenhua Wu

Founder, President and CEO

Founding Team

Exegenesis Bio Investors

Notable investors and investment history

Exegenesis Bio investors
InvestorRounds
BioTrack CapitalSeries B Extension, Series B
TemasekSeries B Extension
Lake Bleu CapitalSeries B Extension
Kaitai CapitalSeries B Extension, Series B
LYFE CapitalSeries B Extension
Hillhouse Capital GroupSeries B Extension
Legend CapitalSeries B Extension, Series B

Exegenesis Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Exegenesis Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Exegenesis Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersHorsham, Pennsylvania
Employee Range17
Year Founded2019
Last FundingJun 23, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.